Literature DB >> 22124352

Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate.

Jenny Z Zhang1, Ezequiel Wexselblatt, Trevor W Hambley, Dan Gibson.   

Abstract

In contrast to the Pt(IV) derivatives of cisplatin, Pt(IV) derivatives of oxaliplatin do not show the expected correlation between the electrochemical reduction potentials and rates of reduction by ascorbate. This is probably due to the lower ability of the amine and carboxylato ligands to form a bridge with the reducing agents to facilitate electron transfer. This journal is © The Royal Society of Chemistry 2012

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22124352     DOI: 10.1039/c1cc16647f

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  22 in total

Review 1.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

Review 2.  Transporter and protease mediated delivery of platinum complexes for precision oncology.

Authors:  Trevor W Hambley
Journal:  J Biol Inorg Chem       Date:  2019-05-15       Impact factor: 3.358

3.  Diamminetetrakis(carboxylato)platinum(IV) complexes--synthesis, characterization, and cytotoxicity.

Authors:  Björn R Hoffmeister; Mahsa S Adib-Razavi; Michael A Jakupec; Markus Galanski; Bernhard K Keppler
Journal:  Chem Biodivers       Date:  2012-09       Impact factor: 2.408

Review 4.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

5.  Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents.

Authors:  Grégory Thiabaud; Guangan He; Sajal Sen; Kathryn A Shelton; Wallace B Baze; Luke Segura; Julie Alaniz; Ruben Munoz Macias; Greg Lyness; Alan B Watts; Hyun Min Kim; Hyunseung Lee; Mi Young Cho; Kwan Soo Hong; Rick Finch; Zahid H Siddik; Jonathan F Arambula; Jonathan L Sessler
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-16       Impact factor: 11.205

6.  Reinterpretation of the vibrational spectroscopy of the medicinal bioinorganic synthon c,c,t-[Pt(NH3)2Cl2(OH)2].

Authors:  Timothy C Johnstone; Stephen J Lippard
Journal:  J Biol Inorg Chem       Date:  2014-02-11       Impact factor: 3.358

7.  Intratumoral Cancer Chemotherapy with a Carrier-Based Immunogenic Cell-Death Eliciting Platinum (IV) Agent.

Authors:  Chad Groer; Ti Zhang; Ruolin Lu; Shuang Cai; Derek Mull; Aric Huang; Melanie Forrest; Cory Berkland; Daniel Aires; Marcus Laird Forrest
Journal:  Mol Pharm       Date:  2020-10-08       Impact factor: 4.939

8.  Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.

Authors:  Gregory Thiabaud; Rebecca McCall; Guangan He; Jonathan F Arambula; Zahid H Siddik; Jonathan L Sessler
Journal:  Angew Chem Int Ed Engl       Date:  2016-07-05       Impact factor: 15.336

9.  Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.

Authors:  Simone Göschl; Ekaterina Schreiber-Brynzak; Verena Pichler; Klaudia Cseh; Petra Heffeter; Ute Jungwirth; Michael A Jakupec; Walter Berger; Bernhard K Keppler
Journal:  Metallomics       Date:  2017-03-22       Impact factor: 4.526

10.  Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity.

Authors:  Verena Pichler; Petra Heffeter; Seied M Valiahdi; Christian R Kowol; Alexander Egger; Walter Berger; Michael A Jakupec; Mathea Sophia Galanski; Bernhard K Keppler
Journal:  J Med Chem       Date:  2012-12-17       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.